A quest to optimize the clinical pharmacology of tuberculosis and human Immunodeficiency virus drug treatment
Daskapan, Alper

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2018

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):
Daskapan, A. (2018). A quest to optimize the clinical pharmacology of tuberculosis and human immunodeficiency virus drug treatment. [Groningen]: Rijksuniversiteit Groningen.

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Development and Validation of a Bioanalytical Method for the Simultaneous Determination of 14 Antiretroviral Drugs using Liquid Chromatography-Tandem Mass Spectrometry

Alper Daskapan1, Kai van Hateren1, Ymkje Stienstra2, Jos Kosterink1,3, Tjip van der Werf1, Daan Touw1,4 Jan-Willem Alffenaar1,*

1University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands. 2University of Groningen, University Medical Center Groningen, Department of Internal Medicine – Infectious Diseases, Groningen, The Netherlands. 3University of Groningen, Groningen Research Institute of Pharmacy, PharmacoTherapy- Epidemiology and-Economy, Groningen, The Netherlands. 4University of Groningen, Groningen Research Institute of Pharmacy, Unit Pharmacokinetics, Toxicology and Targeting, Groningen, The Netherlands

*Correspondence: University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, PO box 30.001, 9700 RB Groningen, The Netherlands. Phone: +31 503614070; Fax: +31 503614087. Email: J.W.C.Alffenaar@umcg.nl

OBJECTIVES: The aim was to develop and validate a LC-MS/MS assay to determine antiretrovirals in human plasma for routine therapeutic drug monitoring.

METHODS: The selectivity, sensitivity, linearity, accuracy, precision, recovery, matrix effect, stability and dilution integrity and carry-over were validated according to EMA and FDA standards.

RESULTS: For accuracy and precision, the highest overall bias was 11.3% at LLOQ of both lopinavir and saquinavir. The highest overall CV was 15.6% at the LLOQ of darunavir. Storage stability at 4°C, 20–25°C and 10°C had a maximum CV of 13.2% at low QC level (0.2 mg/L) for saquinavir. Freeze-thaw stability had a maximum overall bias of 7.4% at low QC level (0.8 mg/L) for tipranavir. Selectivity and specificity showed no interfering peaks of more than 20% of the LLOQ.

CONCLUSIONS: The bioanalytical method is suitable for both TDM in standard care and clinical studies.

KEYWORDS: lc-ms/ms, antiretrovirals, hiv, TDM.

INTRODUCTION
The treatment of Human Immunodeficiency Virus (HIV) has improved significantly over the last three decades. This improvement was entirely due to the broad introduction of antiretroviral (ARV) drugs in a combined treatment regimen (cART) [1]. With the advent of cART the mortality and morbidity associated with HIV-1 infection...
and acquired immunodeficiency syndrome (AIDS) sharply decreased [2]. ARV drugs are designed to intervene in the HIV replicative cycle, which eventually results in an HIV ribonucleic acid (RNA) load decrease and subsequently, the recovery of the host immune system. Currently, 25 ARV drugs have been approved for the treatment of HIV by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [3]. These drugs are divided in six classes, each class representing a target in the HIV life cycle: Nucleoside Reverse Transcriptase Inhibitors (NRTI), Nonnucleoside Reverse Transcriptase Inhibitors (NNRTI), Protease Inhibitors (PI), Fusion Inhibitors (FI), Entry Inhibitors and integrase strand transfer inhibitors (INI) [3].

In order to optimize treatment outcome and to prevent drug resistance, therapeutic drug monitoring (TDM) is recommended in cases of: drug-drug interaction; renal or hepatic morbidity; pregnancy; administration of drug doses not commonly used; virologic failure; suspicion of nonadherence and adverse events [4]. In order to be eligible for TDM a correlation should exist between drug concentrations and effect or adverse effects; or, a drug should have large inter-individual pharmacokinetic variability; or a narrow therapeutic index [5]. In daily practice at this point NNRTIs, PIs and INIs qualify for TDM [5-7]. Previously, several assays have been published describing the simultaneous determination of ARV drugs for TDM [8-11]. The analytical methods described often used UV detection or included an extensive sample preparation such as liquid-liquid extraction. These methods are time-consuming and incur high costs. Liquid chromatography (LC) tandem mass spectrometry (MS) is considered to be the most important analytical technique which is superior to UV detection due to its specificity [12]. Further, using a stable isotope internal standard (IS) for LC tandem MS is highly recommended as it corrects for injection and ionization variability [13]. A stable isotope IS will compensate for these deviations and ensures a robust, high-throughput assay [13]. The aim of this study was to develop and validate a bioanalytical assay to determine both older and new PIs and NNRTIs, and two INIs with a simple sample preparation and using stable isotope IS followed by LC-MS/MS analysis in human plasma as this approach is more cost-effective, less time-consuming than most methods using UV detection or extensive sample preparation.

MATERIALS AND METHODS

Analysis

The following ARVs were included in the method: amprenavir, atazanavir, darunavir, dolutegravir, etravirine, indinavir, lopinavir, nelfinavir, nelfinavir-M8, nevirapine, raltegravir, ritonavir, saquinavir and tipranavir. The corresponding stable isotope IS were used: [2H4]-amprenavir, [13C6]-atzanavir, [13C4,15N]-darunavir, [13C6]-dolutegravir, [13C6]-etravirine, [13C4,15N]-indinavir, [2H3]-lopinavir, [13C6]-nelfinavir, [2H6]-nevirapine, [2H6]-raltegravir, [13C, 2H3]-ritonavir, [13C6]-saquinavir and [2H3]-tipranavir. The ARVs and IS used (Figure 1), were purchased from Alsachim (Illkirch, Graffenstaden, France), except for nelfinavir-M8 which was purchased from Pfizer Inc. (New York, Unites States of America). Acetonitrile for LC-MS/MS was purchased from BioSolve ( Valkenswaard, The Netherlands). The chemicals used, including methanol and trifluoroacetic acid, were of high-pressure liquid chromatography (HPLC) or analytical grade and were purchased from VWR (Amsterdam, The Netherlands). Purified water was obtained from a Milli-Q water purifying system (Millipore Corporation, Billerica, MA, USA).

Both pooled human serum samples and pooled human plasma samples with ethylene diamine tetraacetic acid (EDTA) as anticoagulant (Becton Dickinson Vacutainer®, K.E 7.2 mg) were made available in accordance with the standard operating procedures of our medical center. One milligram of each stable isotope IS was added to methanol to a concentration of 1 g/L and stored at -80°C. The precipitation reagent consisted of a mixture of methanol Li-chrosolv, acetonitrile (4:21, v/v) and IS. Twenty-five microliters per IS was standard spiked.
Figure 1. Chemical structures of the analytes and stable isotope internal standards used in the current bioanalytical method.

1 = Amprenavir, 2 = [2H]4-amprenavir, 3 = Atazanavir, 4 = [2H]4-atazanavir, 5 = Darunavir, 6 = [13C]6-darunavir, 7 = Dolutegravir, 8 = [13C, 2H]2-dolutegravir, 9 = Etravirine, 10 = [13C]6-etravirine, 11 = Indinavir (sulphate), 12 = [13C, 15N]-indinavir, 13 = Lopinavir, 14 = [2H]2-lopinavir, 15 = Nelfinavir (mesylate monohydrate), 16 = [2H]2-50-nelfinavir, 17 = Nevirapine, 18 = [2H]2-nevirapine, 19 = Raltegravir, 20 = [2H]2-raltegravir, 21 = Ritonavir, 22 = [13C, 2H]2-ritonavir, 23 = Saquinavir (mesylate), 24 = [2H]2-251-saquinavir, 25 = Tipranavir, 26 = [2H]2-tipranavir, 27 = Nelfinavir-M8
directly in 250 mL precipitation reagent. To 10 µL of each sample, a volume of 750 µL of precipitation reagents combined with the IS was added to a vial. The samples were vortexed for 1 min. The vials were centrifuged for 5 min at 9500g. Ten microliters of the upper layer was injected into the LC-MS/MS.

The analysis was performed on a triple-quadrupole LC-MS/MS (Thermo Scientific, San Jose, CA, USA) with an MS Pump Plus (Finnigan Surveyor) and autosampler Plus (Finnigan Surveyor). The mass spectrometer was a triple-stage quadrupole Quantum Access Max mass spectrometer. The autosampler temperature was set at 10°C. Liquid chromatographic separation was performed on a HyPURITY C18 analytical column (50 by 2.1 mm, 3 µm particle size; Thermo Scientific, Interscience, Breda, The Netherlands), and the temperature was set at 20°C. The mobile phase had a flow rate of 0.5 mL/min and consisted of purified water, acetonitrile, and an aqueous buffer (containing ammonium acetate [5 g/L], acetic acid [35 mL/L of water], and trifluoroacetic acid [2 mL/L of water]. The method had a run time of 2.9 min and chromatographic separation was performed by means of an elution gradient shown in Table 1. Peak area ratios of the ARVs and their IS were used to calculate concentrations.

The MS was operating in positive electrospray ionization mode and selected reaction monitoring (SRM) mode with a positive spray voltage of 5,000V, a capillary temperature of 350°C, a vaporizer temperature of 150°C and a sheath gas pressure and auxiliary pressure of 60 and 10 arbitrary units, respectively. High-purity argon was used for both the source and collision gas flows and high-purity nitrogen for the sheath gas. The mass transitions used in ARV drug quantification and the detail mass spectrometry conditions are demonstrated in Table 2. A scan width of 0.5 m/z was used for all components. Peak area integration for all components was calculated by Xcalibur software version 2.0.7 (Thermo Fisher, San Jose, CA, USA).

Method validation

The analytical method was validated in accordance with the guidance for Industry of the FDA and the EMA guidelines [14,5]. For the validation of the assay the selectivity, sensitivity, linearity, accuracy, precision, recovery, matrix effect, stability and dilution integrity were determined.

For all components separate stock solutions were made in a concentration of 10 g/L, with the exception of tipranavir; for this drug a stock solution of 20 g/L was made. All stock solutions were diluted to 500 mg/L, except for the stock solution of tipranavir that was diluted to 2 g/L. Dimethylsulfoxide (DMSO) was used as solvent for dilution. Subsequently 1, 2, 5, 10, 25, 50, 100, 150 and 200 µL of each diluted stock solution was spiked to 5 mL EDTA plasma, resulting in a final composition of 4% organic solvent in the calibration.
standards. The analysis for linearity was conducted in 5 replicates per concentration. The selection of the assay range was based on the utilization for TDM in daily practice. The calibration standards, blanks, and quality control (QC) samples were fully thawed at room temperature. The criteria used for the selection of the QC concentration levels were based on FDA and EMA guidelines \[14,15\], LOW was 2 or 3 times the LLOQ; MED was at 40% and HIGH was at 80%. QC samples and calibration standards were stored at -20°C. QC samples with 4 different concentrations of each ARV were used. The concentrations and number of samples used for the calibration curves in combination with the concentrations used for the QC samples per component are shown in Table 3.

| Table 2. Mass transitions and detail mass spectrometry conditions. |
|---------------------------------------------------------------|
| **Component** | **Drug class** | **Parent ion (m/z)** | **Product ion (m/z)** | **SRM collision energy (eV)** | **Typical retention time (min)** |
|----------------|----------------|----------------------|----------------------|-----------------------------|---------------------------------|
| Nevirapine     | NNRTI          | 267.1                | 226.1                | 25                          | 1.30                            |
| \[^{2}H\_4\]-Nevirapine |            | 271.1                | 230.1                | 26                          | 1.30                            |
| Indinavir      | PI             | 614.3                | 364.1                | 29                          | 1.45                            |
| \[^{13}C\_6\,^{2}H\_4\]-Indinavir | | 619.3                | 470.2                | 23                          | 1.45                            |
| Dolutegravir   | INI            | 420.1                | 277.0                | 26                          | 1.50                            |
| \[^{13}C\_6\,^{2}H\_5\]-Dolutegravir | | 426.1                | 277.0                | 27                          | 1.50                            |
| Nelfinavir-M8  | PI             | 584.4                | 330.0                | 33                          | 1.50                            |
| Nelfinavir     |                | 568.3                | 467.2                | 26                          | 1.85                            |
| \[^{2}H\_3\]-Nelfinavir |            | 571.3                | 470.2                | 28                          | 1.85                            |
| Raltegravir    | INI            | 445.1                | 360.9                | 17                          | 1.55                            |
| \[^{2}H\_4\]-Raltegravir |          | 451.2                | 367.1                | 17                          | 1.55                            |
| Saquinavir     | PI             | 671.3                | 433.2                | 42                          | 1.60                            |
| \[^{2}H\_8\]-Saquinavir |         | 680.4                | 433.2                | 42                          | 1.60                            |
| Amprenavir     | PI             | 506.2                | 418.1                | 12                          | 1.75                            |
| \[^{2}H\_4\]-Amprenavir |       | 510.2                | 418.2                | 13                          | 1.75                            |
| Darunavir      | PI             | 548.2                | 392.1                | 14                          | 1.75                            |
| \[^{13}C\_6\]-Darunavir |        | 554.3                | 398.1                | 13                          | 1.75                            |
| Atazanavir     | PI             | 705.4                | 335.1                | 28                          | 2.00                            |
| \[^{2}H\_8\]-Atazanavir |       | 711.4                | 338.1                | 28                          | 2.00                            |
| Ritonavir      | PI             | 721.2                | 197.0                | 39                          | 2.20                            |
| \[^{13}C\_6\,^{2}H\_4\]-Ritonavir | | 725.3                | 201.0                | 38                          | 2.20                            |
| Lopinavir      | PI             | 629.3                | 429.2                | 22                          | 2.30                            |
| \[^{2}H\_8\]-Lopinavir |         | 637.4                | 429.2                | 22                          | 2.30                            |
| Etravirine     | NNRTI          | 435.0                | 303.9                | 37                          | 2.50                            |
| \[^{13}C\_6\]-Etravirine |          | 441.1                | 310.0                | 37                          | 2.50                            |
| Tipranavir     | PI             | 603.2                | 333.0                | 29                          | 2.60                            |
| \[^{2}H\_8\]-Tipranavir |        | 607.2                | 334.1                | 29                          | 2.60                            |

NNRTI: Non-Nucleoside Reverse Transcriptase Inhibitor, PI: Protease Inhibitor, INI: Integrase Inhibitor
For selectivity, 6 pooled human plasma samples were examined for interference and their responses were compared with those of the LLOQ samples. Over 3 days, each day a single calibration curve in plasma was analysed and accuracy was measured by evaluation of five determinations per QC sample on three consecutive days. Precision was divided into within-run and between-run values using the same method as used for the accuracy. The coefficient of variation (CV) for the LLOQ was maximized at 20% deviation and the CV for the other QC samples should not exceed 15%. The recovery was determined on three levels (LOW, MED, and HIGH) and was done in five replicates. The stabilities of the ARVs were tested for storage stability and freeze-thaw stability. Storage stability of the ARVs was examined by storing QC samples at room temperature (20°C to 25°C) in a refrigerator at 4°C and after sample preparation in the autosampler at 10°C, all for 7 days. Stability was also tested using five freeze-thaw cycles at -20°C. All stability tests were done using two different QC levels (LOW and HIGH) in five determinations per concentration. The FDA does not describe a maximum CV requirement for stability, therefore a maximum CV of 15% was used for the current method in accordance with the EMA guidelines [14]. In order to determine potential differences between the analysis of ARVs in human plasma and in human serum, a matrix comparison was performed. Since protein precipitation was the single required sample preparation step in this method, relative recovery was measured by comparing the ratios of integrated peak area of the ARVs and the corresponding IS of the QC samples processed with the average peak area of the recovery samples. Recovery samples (low, med, and high) were post-extraction blank samples spiked at the same concentrations as the QC samples. To determine the dilution integrity, on three consecutive days, for each ARV drug a sample was diluted 10 times and then prepared in five replicates. To determine the carry-over a blank sample

| Component      | Number of samples | Calibration curves Concentrations (mg/L) | QC samples mg/L |
|----------------|-------------------|-----------------------------------------|-----------------|
| Amprenavir     | 8                 | 0.2, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 20.0 | 0.2 0.5 8.0 16.0 |
| Darunavir      |                   |                                         |                 |
| Etravirine     |                   |                                         |                 |
| Lopinavir      |                   |                                         |                 |
| Atazanavir     | 9                 | 0.1, 0.2, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 20.0 | 0.1 0.2 8.0 16.0 |
| Indinavir      |                   |                                         |                 |
| Nelfinavir     |                   |                                         |                 |
| Nelfinavir-M8  |                   |                                         |                 |
| Nevirapine     |                   |                                         |                 |
| Ritonavir      |                   |                                         |                 |
| Saquinavir     |                   |                                         |                 |
| Dolutegravir   | 6                 | 0.2, 0.5, 1.0, 2.5, 5.0, 10.0           | 0.2 0.5 4.0 8.0 |
| Raltegravir    |                   |                                         |                 |
| Tipranavir     | 9                 | 0.4, 0.8, 2.0, 4.0, 10.0, 20.0, 40.0, 60.0, 80.0 | 0.4 0.8 32.0 64.0 |

QC: quality control, LLOQ: lower limit of quantitation

Table 3. Concentrations of calibration standards and QC samples.
Figure 2. Chromatograms of the included antiretrovirals and the corresponding stable isotope internal standards at the LLOQ and blank plasma.
Table 4. Concentrations of calibration standards and QC samples

| Component     | Correlation coefficient (linear range) mg/L | Slope | Intercept | Concentration (mg/L) | Within Run CV(%) | Between Run CV(%) | Overall CV(%) | Overall Bias (%) |
|---------------|---------------------------------------------|-------|-----------|----------------------|------------------|-------------------|---------------|------------------|
| Amprenavir    | 0.999 (0.200-20.0)                          | 0.091 | -0.002    |                      |                  |                   |               |                  |
|               | LLOQ (0.2)                                  | 12.0  | 8.9       | 15.0                 | -4.7             |                   |               |                  |
|               | Low (0.5)                                   | 6.7   | 0.0       | 6.7                  | -4.5             |                   |               |                  |
|               | Medium (8.0)                                | 3.7   | 3.0       | 4.8                  | 0.0              |                   |               |                  |
|               | High (16.0)                                 | 2.7   | 3.0       | 4.1                  | -0.9             |                   |               |                  |
| Atazanavir    | 0.999 (0.100-20.0)                          | 0.115 | -0.00141  |                      |                  |                   |               |                  |
|               | LLOQ (0.1)                                  | 7.7   | 0.0       | 7.7                  | -8.0             |                   |               |                  |
|               | Low (0.2)                                   | 4.3   | 1.2       | 4.5                  | -8.3             |                   |               |                  |
|               | Medium (8.0)                                | 2.6   | 3.5       | 4.4                  | 1.3              |                   |               |                  |
|               | High (16.0)                                 | 1.1   | 3.4       | 3.6                  | 1.8              |                   |               |                  |
| Darunavir     | 0.998 (0.200-20.0)                          | 0.146 | -0.002    |                      |                  |                   |               |                  |
|               | LLOQ (0.2)                                  | 16    | 0.0       | 16                   | -2.0             |                   |               |                  |
|               | Low (0.5)                                   | 6.8   | 2.6       | 7.3                  | -3.9             |                   |               |                  |
|               | Medium (8.0)                                | 3.9   | 5.1       | 6.4                  | 0.3              |                   |               |                  |
|               | High (16.0)                                 | 3.4   | 6.1       | 7.0                  | -0.1             |                   |               |                  |
| Dolutegravir  | 0.999 (0.200-10.0)                          | 0.167 | 0.0       |                      |                  |                   |               |                  |
|               | LLOQ (0.1)                                  | 5.4   | 0.0       | 5.4                  | -5.0             |                   |               |                  |
|               | Low (0.5)                                   | 4.8   | 1.1       | 4.9                  | -9.1             |                   |               |                  |
|               | Medium (4.0)                                | 1.8   | 1.2       | 2.2                  | -3.6             |                   |               |                  |
|               | High (8.0)                                  | 1.9   | 0.0       | 1.9                  | -4.4             |                   |               |                  |
| Entravirine   | 0.998 (0.200-20.0)                          | 0.141 | 0.0       |                      |                  |                   |               |                  |
|               | LLOQ (0.2)                                  | 9.4   | 0.0       | 9.4                  | -1.7             |                   |               |                  |
|               | Low (0.5)                                   | 4.5   | 0.0       | 4.5                  | -1.2             |                   |               |                  |
|               | Medium (8.0)                                | 4.5   | 6.4       | 7.8                  | 1.2              |                   |               |                  |
|               | High (16.0)                                 | 3.2   | 3.1       | 4.5                  | 1.3              |                   |               |                  |
| Indinavir     | 0.998 (0.100-20.0)                          | 0.091 | 0.0       |                      |                  |                   |               |                  |
|               | LLOQ (0.1)                                  | 10    | 0.0       | 10                   | -9.3             |                   |               |                  |
|               | Low (0.2)                                   | 6.6   | 0.0       | 6.6                  | -9.0             |                   |               |                  |
|               | Medium (8.0)                                | 2.2   | 2.0       | 3.0                  | 1.1              |                   |               |                  |
|               | High (16.0)                                 | 1.9   | 3.0       | 3.5                  | -0.9             |                   |               |                  |
| Lopinavir     | 0.999 (0.200-20.0)                          | 0.140 | 0.002     |                      |                  |                   |               |                  |
|               | LLOQ (0.2)                                  | 4.7   | 4.8       | 6.7                  | 11               |                   |               |                  |
|               | Low (0.5)                                   | 4.0   | 1.8       | 4.4                  | 1.7              |                   |               |                  |
|               | Medium (8.0)                                | 1.8   | 3.8       | 4.2                  | 1.0              |                   |               |                  |
|               | High (16.0)                                 | 1.3   | 3.7       | 3.9                  | 0.2              |                   |               |                  |
| Nelfinavir    | 0.999 (0.100-20.0)                          | 0.099 | 0.0       |                      |                  |                   |               |                  |
|               | LLOQ (0.1)                                  | 9.3   | 0.0       | 9.3                  | -4.0             |                   |               |                  |
|               | Low (0.2)                                   | 6.1   | 0.0       | 6.1                  | -2.7             |                   |               |                  |
|               | Medium (8.0)                                | 2.5   | 2.4       | 3.4                  | 1.9              |                   |               |                  |
|               | High (16.0)                                 | 1.8   | 3.4       | 3.9                  | 0.9              |                   |               |                  |

QC: quality control, LLOQ: lower limit of quantitation, CV: coefficient of variation, LLOQ: lower limit of quantification; testing for linearity, accuracy and precision were conducted in 5 replicates.
Table 4. Concentrations of calibration standards and QC samples (continued)

| Component     | Correlation coefficient (linear range) mg/L | Slope | Intercept | Concentration (mg/L) | Within Run CV(%) | Between Run CV(%) | Overall CV(%) | Overall Bias (%) |
|---------------|---------------------------------------------|-------|-----------|----------------------|------------------|------------------|---------------|------------------|
| Nelfinavir M8 | 0.999 (0.100-20.0)                           | 0.158 | 0.0       | LLOQ (0.1)           | 8.7              | 0.0              | 8.7           | -4.0             |
|               |                                             |       |           | Low (0.2)            | 4.2              | 3.6              | 5.5           | -0.3             |
|               |                                             |       |           | Medium (8.0)         | 3.4              | 2.1              | 4.0           | -0.4             |
|               |                                             |       |           | High (16.0)          | 1.9              | 2.8              | 3.4           | -1.0             |
|               |                                             |       |           | LLOQ (0.1)           | 5.0              | 5.0              | 7.1           | -4.0             |
| Nevirapine    | 0.999 (0.100-20.0)                           | 0.335 | -0.002    | Low (0.2)            | 4.7              | 2.1              | 5.2           | -3.3             |
|               |                                             |       |           | Medium (8.0)         | 1.6              | 3.0              | 3.4           | 2.1              |
|               |                                             |       |           | High (16.0)          | 0.8              | 2.2              | 2.4           | 1.4              |
| Raltegravir   | 0.998 (0.200-10.0)                           | 0.143 | -0.001    | LLOQ (0.2)           | 12.0             | 0.0              | 12            | -2.3             |
|               |                                             |       |           | Low (0.5)            | 9.6              | 0.0              | 9.6           | -2.3             |
|               |                                             |       |           | Medium (4.0)         | 5.8              | 0.0              | 5.8           | 2.2              |
|               |                                             |       |           | High (8.0)           | 7.1              | 0.0              | 7.1           | 3.6              |
| Ritonavir     | 0.999 (0.100-20.0)                           | 0.158 | -0.001    | LLOQ (0.1)           | 4.7              | 2.9              | 5.5           | -4.0             |
|               |                                             |       |           | Low (0.2)            | 4.1              | 3.6              | 5.4           | -5.3             |
|               |                                             |       |           | Medium (8.0)         | 1.2              | 3.9              | 4.1           | -0.7             |
|               |                                             |       |           | High (16.0)          | 1.4              | 4.5              | 4.7           | -0.5             |
| Saquinavir    | 0.997 (0.100-20.0)                           | 0.103 | 0.0       | LLOQ (0.1)           | 9.4              | 1.6              | 9.6           | 11               |
|               |                                             |       |           | Low (0.2)            | 7.1              | 0.0              | 7.1           | 1.0              |
|               |                                             |       |           | Medium (8.0)         | 2.1              | 2.2              | 3.0           | -1.3             |
|               |                                             |       |           | High (16.0)          | 2.8              | 2.6              | 3.8           | -1.1             |
| Tipranavir    | 0.999 (0.400-80.0)                           | 0.183 | -0.005    | LLOQ (0.4)           | 5.3              | 0.0              | 5.3           | -0.3             |
|               |                                             |       |           | Low (0.8)            | 5.2              | 1.9              | 5.6           | 2.3              |
|               |                                             |       |           | Medium (32.0)        | 2.0              | 3.5              | 4.1           | 4.5              |
|               |                                             |       |           | High (64.0)          | 3.0              | 3.1              | 4.3           | 2.3              |

QC: quality control, LLOQ: lower limit of quantitation, CV: coefficient of variation, LLOQ: low limit of quantification; testing for linearity, accuracy and precision were conducted in 5 replicates.
was analysed after analysing the highest calibration standard per component.

**Clinical application**

After the method was validated and approved it was used for TDM in standard care. For use in daily practice blood was collected in an EDTA blood collection tube. Whole blood was centrifuged with 9500 x g for 5 min and a minimum of 0.500 mL plasma was transferred to a vial and stored until analysis in a – 80°C refrigerator. For analysis 10 µL of plasma was transferred to a vial and 750 µL of precipitation reagent was added. The sample was vortexed for 1 min and subsequently centrifuged for 5 min at 9500 x g. Ten microliters of the upper layer was injected into the LC-MS/MS. One calibration curve was used containing all 14 components. The performance of the assay is routinely evaluated by participation in the international quality control program of ARV drugs of the Association for Quality Assessment in Therapeutic Drug Monitoring and Clinical Toxicology.

### Table 5. Stability testing results at LOW en HIGH concentrations for the included components

| Component    | Concentration (mg/L) | Refrigerator 4°C (bias) % | Room temp. (bias) % | As stab. 10°C (bias) % | F/T 5 (bias) % |
|--------------|----------------------|---------------------------|---------------------|------------------------|----------------|
| Amprenavir   | Low (0.5)            | 2.4                       | 6.4                 | -8.8                   | -2.9           |
|              | High (16.0)          | 1.3                       | 0.5                 | -9.9                   | -3.0           |
| Atazanavir   | Low (0.2)            | 0.0                       | 11                  | -4.0                   | 0.0            |
|              | High (16.0)          | 1.3                       | 4.0                 | -2.0                   | -2.0           |
| Duranavir    | Low (0.5)            | -6.0                      | 0.4                 | 7.0                    | -5.4           |
|              | High (16.0)          | 0.4                       | 2.7                 | 4.8                    | 0.0            |
| Dolutegravir | Low (0.5)            | -4.8                      | 0.8                 | -6.4                   | -6.3           |
|              | High (8.0)           | 0.6                       | 0.7                 | -6.1                   | -2.0           |
| Etravirine   | Low (0.5)            | -7.6                      | 10                  | 0.5                    | -1.8           |
|              | High (16.0)          | 0.9                       | 2.6                 | 0.5                    | -4.0           |
| Indinavir    | Low (0.2)            | -8.0                      | 6.0                 | -12                    | 0.6            |
|              | High (16.0)          | 1.1                       | 2.3                 | -1.0                   | -1.0           |
| Lopinavir    | Low (0.5)            | 2.8                       | 10                  | 0.4                    | 0.7            |
|              | High (16.0)          | -0.9                      | 1.9                 | 0.1                    | -3.0           |
| Nelfinavir   | Low (0.2)            | 2.0                       | 10                  | 0.0                    | 6.6            |
|              | High (16.0)          | -0.8                      | 1.1                 | 0.8                    | 0.0            |
| Nelfinavir_M8| Low (0.2)            | -2.0                      | 1.0                 | -6.0                   | 0.4            |
|              | High (16.0)          | -6.8                      | 1.1                 | -2.9                   | -3.0           |
| Nevirapine   | Low (0.5)            | 10                        | 12                  | -2.0                   | 1.2            |
|              | High (16.0)          | 4.2                       | 6.1                 | 2.5                    | 3.0            |
| Raltegravir  | Low (0.5)            | 3.2                       | -1.6                | -3.2                   | -3.7           |
|              | High (8.0)           | 7.1                       | 4.7                 | 4.8                    | 1.0            |
| Ritonavir    | Low (0.2)            | -4.0                      | 6.0                 | -5.0                   | 1.2            |
|              | High (16.0)          | 0.2                       | 0.8                 | -0.2                   | -2.0           |
| Saquinavir   | Low (0.2)            | 10                        | 13                  | 2.0                    | 6.0            |
|              | High (16.0)          | -0.4                      | -2.3                | 0.1                    | -5.0           |
| Tipranavir   | Low (0.8)            | 4.0                       | 12                  | -2.0                   | 7.4            |
|              | High (64.0)          | 6.9                       | 4.7                 | 1.0                    | 2.0            |

Temp: temperature, AS stab: autosampler stability, F/T 5: stability of 5 freeze and thaw cycles.
Statistics
Results were analysed using one-way analysis of variance (ANOVA) in validated Excel sheets (Microsoft, Redmond, WA).

RESULTS
Method development
For this bioanalytical method several points of consideration were identified regarding mobile- and stationary phase, sample pre-treatment, MS parameters and usability in daily clinical practice. Earlier studies showed adequate liquid-liquid extraction [8,10,17], however simple sample precipitation was preferred for the current method since it is less time-consuming and less expensive [18]. The precipitation reagent has been used for many other bioanalytical methods in the current composition, among others for the determination of azole antifungals and ertapenem [19,20], and therefore was found to be suitable for this bioanalytical method. In order to obtain adequate retention of the highly polar ARVs an analytical column with high stability under aqueous mobile phase conditions was required. The HyPURITY C18 analytical column has a good polar retention capacity and showed adequate peak shape, retention time and has been extensively used in our daily routine making it a sufficient column for bioanalytical determinations in daily practice in combination with the mobile phase used in a stepwise gradient as demonstrated in Table 1. Since the particle diameter of the HyPURITY C18 analytical column was 3 µm the flow rate of the mobile phase was set at 0.5 mL/min in order to ensure optimized resolution and retention time (Figure 2). When the flow rate of the mobile phase was set at 0.5 mL/min it was important to set the detector capillary temperature at 350°C. The adjustments of these parameters was necessary to maximize the ionization and subsequently the sensitivity of the detector.

Method validation results
The validation results for linearity, accuracy and precision are demonstrated in Table 4. For accuracy and precision, the highest overall bias found during the validation was 11.3% at LLOQ of both lopinavir and saquinavir. The highest overall CV was 15.6% at the LLOQ of darunavir. The results for the storage- and freeze-thaw stability are displayed in Table 5. Storage stability in a refrigerator (4°C), at room temperature (20 – 25°C) and in a freezer (−20°C) was found to be adequate. The results for the stability of atazanavir are demonstrated in Table 5. For all components the stability in all conditions was found to be adequate. The results for the homogeneity of the reagents used in the mobile phase are demonstrated in Table 6. The homogeneity was found to be adequate for all reagents except for the phosphoric acid and formic acid. The results for the homogeneity of the HPLC grade water used in the mobile phase are demonstrated in Table 6. The homogeneity was found to be adequate.

| Component      | Number of samples | Median (IQR) concentration (mg/L) |
|----------------|-------------------|-----------------------------------|
| Atazanavir     | 50                | 1.4 (0.9-1.9)                     |
| Darunavir      | 142               | 3.0 (2.1-4.8)                     |
| Etravirine     | 7                 | 0.6 (0.5-0.8)                     |
| Lopinavir      | 65                | 7.7 (3.9-10.9)                    |
| Nevirapine     | 62                | 5.6 (3.9-7.2)                     |
| Ritonavir      | 1                 | 3.1*                             |
| Raltegravir    | 75                | 0.75 (0.2-1.8)                    |
| Saquinavir     | 1                 | 0.5*                             |
| #: 1 sample    |                   |                                   |

Table 6. Components analysed in the period from January 2016 until May 2017 for therapeutic drug monitoring (total = 403 samples).
the autosampler (10°C) met the requirements with a maximum CV of 13.2% at low QC level (0.2 mg/L) for saquinavir. Furthermore, freeze-thaw stability was within FDA and EMA margins, with a maximum overall bias of 7.4% at low QC level (0.8 mg/L) for tipranavir. Selectivity and specificity showed no interfering peaks of more than 20% of the LLOQ. For the matrix comparison the integrated peak height ratio of a component and its corresponding IS in plasma was compared to that in serum and no statistically significant difference between the two matrices was found for each component. Recovery samples (LOW, MED, HIGH) were assayed and recovery of all components was higher than 85%, with the most deviating recovery of 93.4% at low QC level for etravirine. The dilution integrity was proven with a maximum overall bias of 5% for raltegravir. The carry-over testing showed that there was no carry-over. All results of the method validation were within the EMA and FDA guidelines.

Clinical application results
This method has successfully been used in clinical practice for TDM in cases of drug-drug interactions, renal or hepatic morbidities, pregnancy, virologic failure, suspicion of nonadherence and adverse events and it was also used in a clinical study on darunavir pharmacokinetics [21]. In the period from January 2016 until May 2017 403 plasma samples were analysed using this bioanalytical method (Table 6). Performance of the assay was within the accepted margins (accuracy and precision <20%) of the international quality control program of ARV drugs of the KKGT in our laboratory.

DISCUSSION AND CONCLUSION
The bioanalytical method described here is rapid and simple and provides an efficient tool for TDM of ARV drugs. This bioanalytical method contains both new ARVs as older ARVs such as tipranavir, saquinavir, indinavir and nelfinavir, making it also suitable for resource limited settings were these drugs are currently commonly used. We were struck by the good bias and precision data illustrating the robustness of our analysis. Previously, other comparable assays have been published describing the simultaneous determination of PIs, NNRTs and INIs [8, 10, 17, 22]. Three of these studies required a time consuming liquid-liquid extraction and did not include stable isotope IS [8, 10, 17], what could result in a poorer compensation for inefficiencies in extraction and sample preparation steps, as well as for any matrix effect. One of these bioanalytical methods contained 17 ARVs, but required liquid-liquid extraction and did not include stable isotope IS [8]. All four of these studies had a relatively long run time varying from 10 – 30 min. For TDM purposes a relatively small sample volume and simple sample preparation is desirable. Therefore, the method described by Kromdijk et al. appears to be the best applicable in daily practice compared to the other three methods published [22]. The current described bioanalytical method has a shorter run time and includes more ARVs which can be determined simultaneously than the study of Kromdijk et al. Due to the simple sample preparation, which only included protein precipitation using a precipitation reagent, no time-consuming and expensive liquid-liquid extractions and solid-phase extractions were required. The short run time of 2.9 min, the use of small volumes of plasma and the possibility of the simultaneous determination of 14 ARV drugs makes the method we described highly suitable for routine service. The currently developed method and the applicability for routine service is supported by a recent study by Baldelli et al. [18] where a bioanalytical method for elvitegravir was developed similar to the current one. Baldelli et al. utilized the quality by design approach for the method development which entails a systematic method for quality standards by looking at the entire development system and product life cycle [18].

In the current bioanalytical method overlapping retention times of some components were demonstrated. For the development of this method we achieved a high resolution on the one hand and a fast run-time on the other hand. However, due to its desired applicability
for routine service to clinicians, and the high sensitivity and discriminatory power of LC-MS/MS, a faster run-time prevailed over higher resolution. The bioanalytical method was simple, specific, robust, reproducible and demonstrated a high sensitivity for all components and better cost-effectiveness than the commonly used methods. Our assay platform is suitable for TDM in standard care and in clinical studies for old and new ARVs.

REFERENCES
1. Hull MW, Montaner J. Antiretroviral therapy: a key component of a comprehensive HIV prevention strategy. Curr HIV/AIDS Rep 8(2), 85-93 (2011).
2. Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med 2(4), a007161 (2012).
3. U.S. Department of Health and Human Services. U.S. Food and Drug Administration: Antiretroviral drugs used in the treatment of HIV infection. 2017(9/19) (2016). https://www.fda.gov/forpatients/illness/hivaids/treatment/ucm118915.htm
4. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Departmet of Health and Human Services. 2017(9/19) (2017). https://aidsinfo.nih.gov/guidelines.
5. Punyawudho B, Singkham N, Thammajaruk N et al. Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients. Expert Rev Clin Pharmacol 9(12), 1583-1595 (2016).
6. Acosta EP, Gerber JG, Adult Pharmacology Committee of the AIDS Clinical Trials Group. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses 18(12), 825-834 (2002).
7. Burger D, Krens S, Robijns K, Aarnoutse R, Bruggemann R, Touw D. Poor performance of laboratories assaying newly developed antiretroviral agents: results for darunavir, etravirine, and raltegravir from the international quality control program for therapeutic drug monitoring of antiretroviral drugs in human plasma/serum. Ther Drug Monit 36(6), 824-827 (2014).
8. Jung BH, Rezk NL, Bridges AS, Corbett AH, Kashuba AD. Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 21(10), 1095-1104 (2007).
9. Proust V, Toth K, Hulin A, Taburet AM, Gimenez F, Singlas E. Simultaneous high-performance liquid chromatographic determination of the antiretroviral agents amprenavir, nelfinavir, ritonavir, saquinavir, delavirdine and efavirenz in human plasma. J Chromatogr B Biomed Sci Appl 742(2), 453-458 (2000).
10. Turner ML, Reed-Walker K, King JR, Acosta EP. Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 784(2), 331-341 (2003).
11. Villani P, Feroggio M, Gianelli L et al. Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography–mass spectrometry assay. Ther Drug Monit 23(4), 380-388 (2001).
12. Veringa A, Sturkenboom MG, Dekkers BG et al. LC-MS/MS for therapeutic drug monitoring of anti-infective drugs. TrAC Trends in Analytical Chemistry. 84, 34-40 (2016).
13. Lowes S, Jersey J, Shoup R et al. Recommendations on: internal standard criteria, stability, incurred sample reanalysis and recent 483s by the Global CRO Council for Bioanalysis. Bioanalysis 3(12), 1323-1332 (2011).
14. European Medicine Agency (EMA), Committe for Medicinal Product for Human Use. Guideline on bioanalytical method validation. 2017 (2012). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf
15. U.S. Department of Health and Human Services Food and Drug Administration. Guidance for industry, bioanalytical method validation. Center for Drug Evaluation and Research, Rockville, MD. 2017 (2001). https://www.fda.gov/downloads/Drugs/Guidance/ucm070107.pdf

16. Burger D, Teulen M, Eerland J, Harteveld A, Aarnoutse R, Touw D. The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma: a global proficiency testing program. Ther Drug Monit 33(2), 239-243 (2011).

17. Fayet A, Beguin A, Zanolari B et al. A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine. J Chromatogr B Analyt Technol Biomed Life Sci 877(11-12), 1057-1069 (2009).

18. Baldelli S, Marrubini G, Cattaneo D, Clementi E, Cerea M. Application of Quality by Design Approach to Bioanalysis: Development of a Method for Elvitegravir Quantification in Human Plasma. Ther Drug Monit 39(5), 531-542 (2017).

19. Alffenaar JW, Wessels AM, van Hateren K, Greijdanus B, Kosterink JG, Uges DR. Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 878(1), 39-44 (2010).

20. van Rijn SP, Wessels AM, Greijdanus B, Touw DJ, Alffenaar JW. Quantification and validation of etrapenem using a liquid chromatography-tandem mass spectrometry method. Antimicrob Agents Chemother 58(6), 3481-3484 (2014).

21. Daskapan A, Dijkema D, de Weerd DA et al. Food intake and darunavir plasma concentrations in people living with HIV in an outpatient setting. Br J Clin Pharmacol 83(10), 2325-2329 (2017).

22. Kromdijk W, Pereira SA, Rosing H, Mulder JW, Beijnen JH, Huitema AD. Development and validation of an assay for the simultaneous determination of zidovudine, abacavir, emtricitabine, lamivudine, tenofovir and ribavirin in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 919-920, 43-51 (2013).